Cabazitaxel

ArtNr	S3022-10
Hersteller	Selleckchem
CAS-Nr.	183133-96-2
Menge	10 mg
Quantity options	10 mg 100 mg 1 g 10 g 10 mM/1 mL 200 mg 5 mg 5 g
Kategorie	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Colorectal Cancer Brain Cancer
Typ	Inhibitors
Specific against	other
Smiles	CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)OC)C)OC
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	XRP6258,RPR-116258A,TXD 258,Taxoid XRP6258
Similar products	Cabazitaxel
Lieferbar
Storage Conditions	2 years -80 in solvent
Molecular Weight	835, 93
Animal Models	Murine tumor xenografts (colon C38 and pancreas P03)
Clinical Trials	Cabazitaxel has entered in a phase I clinical trial in the treatment of solid cancer.
In vitro	Cabazitaxel increases CYP3A enzyme activities in rat hepatocytes. The mean ex-vivo human plasma protein binding of Cabazitaxel is 91.6%. Cabazitaxel is rapidly and extensively metabolised in numerous metabolites. Cabazitaxel demonstrates activity in several murine and human resistant cell lines. [1] With a 4-day exposure to cabazitaxel, cytotoxicity is noted with relatively low cabazitaxel concentrations. Cabazitaxel shows high antitumor activity in 3 human colorectal cell lines (HCT-116, HCT-8, and HT-29). [2]
In vivo	In accompanying models, Cabazitaxel is noted to have significant antitumor activity. In murine tumor xenografts (colon C38 and pancreas P03), Cabazitaxel elicites complete tumor regressions. Using SF-295 and U251 human glioblastoma cell lines, both orthotopic and subcutaneous murine xenografts are generated. Cabazitaxel treatment leads to complete regression in the majority of subcutaneously implanted tumors. Furthermore, in orthotopic models, Cabazitaxel leads to complete tumor regression in 4 out of 10 U251 tumors. [2]
Solubility (25C)	DMSO 100 mg/mL, Water <1 mg/mL, Ethanol <1 mg/mL
Information	Cabazitaxel is a semi-synthetic derivative of a natural taxoid that kills cancer cells by inhibiting cell division and growth. Cabazitaxel exerts its effects by inhibiting microtubule growth and assembly, processes that are essential for cells to divide. Cabazitaxel induces autophagy via the PI3K/Akt/mTOR pathway.
Chemical Name	Benzenepropanoic acid, -[[(1, 1-dimethylethoxy)carbonyl]amino]--hydroxy-, (2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-11-hydroxy-4, 6-dimethoxy-4a, 8, 13, 13-tetramethyl-5-oxo-7, 11-methano-1H-cyclodeca[3, 4]benz[1, 2-b]oxet-9-yl ester, (R, S)-
Features	Cabazitaxel is a semi-synthetic derivative of a natural taxoid.

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

S3022-10-datasheet.pdf

S3022-10-safety-datasheet.pdf